US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Therapeutics

8.40

-0.5400-6.04%

Post-market: 8.500.1000+1.19%19:16 EDT

Volume:1.39M

Turnover:12.03M

Market Cap:262.84M

PE:-2.95

High:9.25

Open:8.90

Low:8.40

Close:8.94

52wk High:50.40

52wk Low:8.40

Shares:31.29M

Float Shares:15.69M

Volume Ratio:0.67

T/O Rate:8.88%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.8500

EPS(LYR):-2.8503

ROE:-33.63%

ROA:-21.86%

PB:0.92

PE(LYR):-2.95

Loading ...

Overview Company News Filings

Intensity Therapeutics issued new patent in the US

LENZ Therapeutics Q4 net loss widens on VIZZ launch costs

LENZ Q4 net loss rises 184% to USD 35.9 million, SG&A expenses jump 323% to USD 40 million

LENZ Therapeutics Q4 EPS $(1.16) Misses $(0.96) Estimate, Sales $1.588M Miss $1.886M Estimate

Lenz Therapeutics Inc - Q4 2025 Product Revenue Approx $1.6 Mln

THOMSON REUTERS

Lenz Therapeutics Q4 Net Income USD -35.896 Million

THOMSON REUTERS

Lenz Therapeutics Q4 Income From Operations USD -38.463 Million

THOMSON REUTERS

Lenz Therapeutics Q4 Operating Expenses USD 40.051 Million

THOMSON REUTERS

Press Release: Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer

Press Release: LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

CAMP4 Therapeutics Adds Veteran CFO MacLean to Board

Wedbush Raises Price Target on Avalo Therapeutics to $29 From $28, Keeps Outperform Rating

MT Newswires Live

Context Therapeutics price target raised to $7 from $4 at Piper Sandler

Avalo Therapeutics Price Target Maintained With a $40.00/Share by BTIG

Serina Therapeutics to Present at the 38th Annual Roth Conference

Relmada Therapeutics initiated with an Overweight at Piper Sandler

Cutia Therapeutics' Loss Narrows in 2025 as Revenue Rises

MT Newswires Live

Cutia Therapeutics Boosts Revenue and Margins as Key Dermatology Products Launch in 2025

Qyuns Therapeutics Invests 100 Million Yuan in Wealth Management Product

MT Newswires Live

Avalo Therapeutics: Attractive Risk‑Reward in Hidradenitis Suppurativa Driven by Abdakibart’s Differentiated IL‑1β Profile and Upcoming Phase 2 LOTUS Readout

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/LENZ/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LENZ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":8.4,"timestamp":1774641600000,"preClose":8.94,"halted":0,"volume":1393631,"hourTrading":{"tag":"盘后","latestPrice":8.5,"preClose":8.4,"latestTime":"19:16 EDT","volume":25181,"amount":211529.72,"timestamp":1774653413550,"change":0.1,"changeRate":0.011905,"amplitude":0.011905},"delay":0,"changeRate":-0.060402684563758295,"floatShares":15692500,"shares":31289969,"eps":-2.85,"marketStatus":"Market Closed","change":-0.54,"latestTime":"03-27 16:00:00 EDT","open":8.9,"high":9.25,"low":8.395,"amount":12026989.540177,"amplitude":0.095638,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.85,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":8.94,"preHourTrading":{"tag":"盘前","latestPrice":8.95,"preClose":8.94,"latestTime":"09:25 EDT","volume":2891,"amount":25925.149467,"timestamp":1774617913255,"change":0.01,"changeRate":0.001119,"amplitude":0.016779},"postHourTrading":{"tag":"盘后","latestPrice":8.5,"preClose":8.4,"latestTime":"19:16 EDT","volume":25181,"amount":211529.72,"timestamp":1774653413550,"change":0.1,"changeRate":0.011905,"amplitude":0.011905},"volumeRatio":0.670644,"impliedVol":1.3191,"impliedVolPercentile":0.9877},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","floatShares":15692500,"roa":"-21.86%","roe":"-33.63%","lyrEps":-2.850329,"volumeRatio":0.670644,"shares":31289969,"dividePrice":0,"high":9.25,"amplitude":0.095638,"preClose":8.94,"low":8.395,"week52Low":8.395,"pbRate":"0.92","psRate":"13.77","week52High":50.4,"institutionHeld":0,"latestPrice":8.4,"eps":-2.85,"divideRate":0,"volume":1393631,"delay":0,"ttmEps":-2.85,"open":8.9,"prevYearClose":16,"prevWeekClose":10.48,"prevMonthClose":13.49,"prevQuarterClose":16,"fiveDayClose":10.48,"twentyDayClose":13.49,"sixtyDayClose":16.12},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LENZ\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-03-24","symbol":"LENZ","fiscalQuarterEnding":"2025/12","expectedEps":-0.91,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1774324800000,"reportTimeType":"pre","actualEps":-1.16},{"market":"US","date":"2026-01-07","symbol":"LENZ","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1767762000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-11-05","symbol":"LENZ","fiscalQuarterEnding":"2025/09","expectedEps":-0.67,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762318800000,"reportTimeType":"pre","actualEps":-0.59},{"market":"US","date":"2025-07-30","symbol":"LENZ","fiscalQuarterEnding":"2025/06","expectedEps":-0.58,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1753848000000,"reportTimeType":"pre","actualEps":-0.53},{"market":"US","date":"2024-05-08","symbol":"LENZ","fiscalQuarterEnding":"2024/03","expectedEps":-0.84,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715140800000,"reportTimeType":"pre","actualEps":-3.53}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LENZ\",market:\"US\",,,undefined,":[{"executeDate":"2024-03-22","recordDate":"2024-03-18","paymentDate":"2024-03-21","value":1.03,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LENZ\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5714,"buy":0.4286,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5714,"analysts":7,"updateTime":1742270400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LENZ\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LENZ","date":"2026-03-27","current":-2.947368,"percent":1,"low":-26.69966,"twenty":-16.980184,"median":-11.233899,"eighty":-7.489126,"high":-3.413108,"avg":-12.467749,"sd":5.207963,"marketCap":280308282},"quantilePoints":[{"date":"2024-03-28","current":-7.959158,"twenty":-7.219077,"median":-6.108955,"eighty":-6.016992,"marketCap":556886354},{"date":"2024-04-05","current":-7.492045,"twenty":-7.873034,"median":-7.667213,"eighty":-6.662191,"marketCap":524203432},{"date":"2024-04-12","current":-7.929963,"twenty":-7.855517,"median":-7.667213,"eighty":-7.432197,"marketCap":554843672},{"date":"2024-04-19","current":-6.382653,"twenty":-7.855517,"median":-7.488396,"eighty":-6.783348,"marketCap":446581492},{"date":"2024-04-26","current":-5.638193,"twenty":-7.716113,"median":-7.451903,"eighty":-5.889996,"marketCap":394493084},{"date":"2024-05-03","current":-5.988527,"twenty":-7.671592,"median":-6.864363,"eighty":-5.803142,"marketCap":419005276},{"date":"2024-05-10","current":-5.317808,"twenty":-7.667213,"median":-6.108955,"eighty":-5.803142,"marketCap":393230653},{"date":"2024-05-17","current":-5.708011,"twenty":-7.597146,"median":-6.0013,"eighty":-5.749862,"marketCap":422084590},{"date":"2024-05-24","current":-5.428308,"twenty":-7.489126,"median":-6.006774,"eighty":-5.719496,"marketCap":401401679},{"date":"2024-05-31","current":-5.355793,"twenty":-7.479638,"median":-5.988527,"eighty":-5.522773,"marketCap":396039443},{"date":"2024-06-07","current":-5.193496,"twenty":-7.457742,"median":-5.904593,"eighty":-5.428999,"marketCap":384038248},{"date":"2024-06-14","current":-6.433167,"twenty":-7.451903,"median":-5.930138,"eighty":-5.428308,"marketCap":475706952},{"date":"2024-06-21","current":-6.236339,"twenty":-7.425628,"median":-5.992177,"eighty":-5.43107,"marketCap":461152311},{"date":"2024-06-28","current":-6.150011,"twenty":-7.389135,"median":-6.0013,"eighty":-5.439358,"marketCap":454768696},{"date":"2024-07-05","current":-6.098214,"twenty":-7.269437,"median":-6.014073,"eighty":-5.469746,"marketCap":450938528},{"date":"2024-07-12","current":-6.771573,"twenty":-6.771573,"median":-6.098214,"eighty":-5.493918,"marketCap":500730721},{"date":"2024-07-15","current":-7.261916,"twenty":-7.163847,"median":-6.103393,"eighty":-5.509112,"marketCap":536989651},{"date":"2024-08-02","current":-8.498134,"twenty":-7.266429,"median":-6.108573,"eighty":-5.524305,"marketCap":628403011},{"date":"2024-08-09","current":-8.328931,"twenty":-7.474529,"median":-6.146558,"eighty":-5.597209,"marketCap":615891126},{"date":"2024-08-16","current":-8.944708,"twenty":-7.671592,"median":-6.236339,"eighty":-5.641258,"marketCap":621424629},{"date":"2024-08-23","current":-8.79431,"twenty":-7.94748,"median":-6.352018,"eighty":-5.670717,"marketCap":610975896},{"date":"2024-08-30","current":-8.746816,"twenty":-8.006409,"median":-6.382653,"eighty":-5.719496,"marketCap":607676296},{"date":"2024-09-06","current":-9.451311,"twenty":-8.199004,"median":-6.419354,"eighty":-5.743293,"marketCap":656620360},{"date":"2024-09-13","current":-8.17293,"twenty":-8.352945,"median":-6.434893,"eighty":-5.773217,"marketCap":567806132},{"date":"2024-09-20","current":-8.7389,"twenty":-8.507104,"median":-6.459289,"eighty":-5.788545,"marketCap":607126363},{"date":"2024-09-27","current":-8.806184,"twenty":-8.638371,"median":-6.616182,"eighty":-5.792924,"marketCap":611800796},{"date":"2024-10-04","current":-8.897214,"twenty":-8.745233,"median":-7.269437,"eighty":-5.800953,"marketCap":618125029},{"date":"2024-10-11","current":-9.340491,"twenty":-8.850511,"median":-7.455552,"eighty":-5.81701,"marketCap":648921294},{"date":"2024-10-18","current":-10.417023,"twenty":-8.905129,"median":-7.492045,"eighty":-5.857882,"marketCap":723712222},{"date":"2024-10-25","current":-9.902504,"twenty":-9.0017,"median":-7.670862,"eighty":-5.904593,"marketCap":687966558},{"date":"2024-10-31","current":-10.939457,"twenty":-9.257377,"median":-7.718702,"eighty":-5.904593,"marketCap":760007820},{"date":"2024-11-08","current":-14.709443,"twenty":-9.419648,"median":-7.959158,"eighty":-5.955683,"marketCap":894466512},{"date":"2024-11-15","current":-15.344855,"twenty":-9.514636,"median":-8.00261,"eighty":-5.970448,"marketCap":933105265},{"date":"2024-11-22","current":-15.521232,"twenty":-9.76398,"median":-8.132103,"eighty":-5.988527,"marketCap":943830613},{"date":"2024-11-29","current":-16.100113,"twenty":-9.924668,"median":-8.17293,"eighty":-5.994366,"marketCap":979031755},{"date":"2024-12-06","current":-16.33076,"twenty":-10.388526,"median":-8.285117,"eighty":-6.004584,"marketCap":993057210},{"date":"2024-12-13","current":-13.920266,"twenty":-10.815972,"median":-8.351032,"eighty":-6.018452,"marketCap":846477455},{"date":"2024-12-20","current":-13.694141,"twenty":-11.182468,"median":-8.50374,"eighty":-6.082845,"marketCap":832727009},{"date":"2024-12-27","current":-14.476534,"twenty":-12.093039,"median":-8.531114,"eighty":-6.098214,"marketCap":880303552},{"date":"2025-01-03","current":-12.794163,"twenty":-13.449021,"median":-8.618187,"eighty":-6.102358,"marketCap":778000234},{"date":"2025-01-10","current":-11.912274,"twenty":-13.190334,"median":-8.707238,"eighty":-6.108649,"marketCap":724373495},{"date":"2025-01-17","current":-10.130408,"twenty":-13.019383,"median":-8.746816,"eighty":-6.115785,"marketCap":616019980},{"date":"2025-01-24","current":-11.197719,"twenty":-12.871045,"median":-8.79431,"eighty":-6.143105,"marketCap":680922085},{"date":"2025-01-31","current":-11.523339,"twenty":-12.794163,"median":-8.877425,"eighty":-6.150011,"marketCap":700722728},{"date":"2025-02-07","current":-12.070562,"twenty":-12.328345,"median":-8.905129,"eighty":-6.232886,"marketCap":733998807},{"date":"2025-02-14","current":-11.432889,"twenty":-12.292165,"median":-8.964497,"eighty":-6.236339,"marketCap":695222549},{"date":"2025-02-21","current":-11.279124,"twenty":-12.151063,"median":-8.998138,"eighty":-6.308164,"marketCap":685872246},{"date":"2025-02-28","current":-9.62841,"twenty":-12.079607,"median":-9.059485,"eighty":-6.342695,"marketCap":585493990},{"date":"2025-03-07","current":-10.297741,"twenty":-11.943932,"median":-9.320702,"eighty":-6.355126,"marketCap":626195310},{"date":"2025-03-14","current":-11.193196,"twenty":-11.879712,"median":-9.419648,"eighty":-6.365485,"marketCap":680647077},{"date":"2025-03-21","current":-14.554795,"twenty":-11.943932,"median":-9.482973,"eighty":-6.379634,"marketCap":724377586},{"date":"2025-03-28","current":-14.68208,"twenty":-12.421509,"median":-9.574004,"eighty":-6.398202,"marketCap":730712447},{"date":"2025-04-04","current":-12.728528,"twenty":-13.089934,"median":-9.668992,"eighty":-6.415901,"marketCap":633486102},{"date":"2025-04-11","current":-10.2603,"twenty":-12.90813,"median":-9.741473,"eighty":-6.42488,"marketCap":510644883},{"date":"2025-04-17","current":-12.761733,"twenty":-12.945214,"median":-9.779811,"eighty":-6.430405,"marketCap":635138674},{"date":"2025-04-25","current":-15.833323,"twenty":-13.271407,"median":-9.84549,"eighty":-6.435239,"marketCap":788008663},{"date":"2025-05-02","current":-15.982746,"twenty":-13.932929,"median":-9.940463,"eighty":-6.440764,"marketCap":795445305},{"date":"2025-05-09","current":-15.25222,"twenty":-14.136351,"median":-10.102399,"eighty":-6.452984,"marketCap":728141003},{"date":"2025-05-16","current":-16.118891,"twenty":-14.245886,"median":-10.138549,"eighty":-6.460191,"marketCap":769515850},{"date":"2025-05-23","current":-16.637714,"twenty":-14.356129,"median":-10.19625,"eighty":-6.460792,"marketCap":794284465},{"date":"2025-05-30","current":-17.410053,"twenty":-14.523491,"median":-10.236057,"eighty":-6.585104,"marketCap":831155927},{"date":"2025-06-06","current":-17.864023,"twenty":-14.65894,"median":-10.342966,"eighty":-6.96771,"marketCap":852828466},{"date":"2025-06-13","current":-17.439532,"twenty":-14.747436,"median":-10.384797,"eighty":-7.264924,"marketCap":832563235},{"date":"2025-06-20","current":-17.704839,"twenty":-14.88454,"median":-10.454615,"eighty":-7.299361,"marketCap":845229004},{"date":"2025-06-27","current":-17.752005,"twenty":-15.005667,"median":-10.623361,"eighty":-7.425628,"marketCap":847480696},{"date":"2025-07-03","current":-19.178768,"twenty":-15.33581,"median":-10.694071,"eighty":-7.451903,"marketCap":915594389},{"date":"2025-07-11","current":-20.198727,"twenty":-15.529319,"median":-10.766979,"eighty":-7.459202,"marketCap":964287236},{"date":"2025-07-18","current":-20.381494,"twenty":-15.833323,"median":-10.791578,"eighty":-7.484747,"marketCap":973012543},{"date":"2025-07-25","current":-19.691695,"twenty":-16.100113,"median":-11.044571,"eighty":-7.492045,"marketCap":940081543},{"date":"2025-08-01","current":-16.20487,"twenty":-16.158905,"median":-11.077981,"eighty":-7.667213,"marketCap":849102797},{"date":"2025-08-08","current":-17.484059,"twenty":-16.20487,"median":-11.141188,"eighty":-7.667213,"marketCap":916129723},{"date":"2025-08-15","current":-22.268769,"twenty":-16.33076,"median":-11.193196,"eighty":-7.674511,"marketCap":1166838947},{"date":"2025-08-22","current":-21.691773,"twenty":-16.434778,"median":-11.220775,"eighty":-7.693556,"marketCap":1136605525},{"date":"2025-08-29","current":-20.793619,"twenty":-16.611183,"median":-11.233899,"eighty":-7.743848,"marketCap":1089544067},{"date":"2025-09-05","current":-21.729877,"twenty":-16.749673,"median":-11.252126,"eighty":-7.89274,"marketCap":1138602072},{"date":"2025-09-12","current":-22.214335,"twenty":-16.928962,"median":-11.290275,"eighty":-7.953319,"marketCap":1163986737},{"date":"2025-09-19","current":-22.693351,"twenty":-17.073997,"median":-11.339198,"eighty":-7.982513,"marketCap":1189086182},{"date":"2025-09-26","current":-21.789753,"twenty":-17.210778,"median":-11.419321,"eighty":-7.998378,"marketCap":1141739502},{"date":"2025-10-03","current":-26.302295,"twenty":-17.347559,"median":-11.473592,"eighty":-8.003646,"marketCap":1378187678},{"date":"2025-10-10","current":-25.175521,"twenty":-17.497557,"median":-11.534645,"eighty":-8.0071,"marketCap":1319146940},{"date":"2025-10-17","current":-22.018374,"twenty":-17.690689,"median":-11.749464,"eighty":-8.107241,"marketCap":1153718783},{"date":"2025-10-24","current":-16.034033,"twenty":-17.707197,"median":-11.991418,"eighty":-8.145558,"marketCap":840151237},{"date":"2025-10-31","current":-15.563946,"twenty":-17.690689,"median":-12.292165,"eighty":-8.168128,"marketCap":815519652},{"date":"2025-11-07","current":-10.439663,"twenty":-17.665927,"median":-12.292165,"eighty":-8.196087,"marketCap":614718687},{"date":"2025-11-14","current":-14.07658,"twenty":-17.595178,"median":-12.325665,"eighty":-8.25011,"marketCap":828871278},{"date":"2025-11-21","current":-14.730193,"twenty":-17.553908,"median":-12.761733,"eighty":-8.286974,"marketCap":867357940},{"date":"2025-11-28","current":-16.218091,"twenty":-17.524554,"median":-12.861347,"eighty":-8.308212,"marketCap":954969853},{"date":"2025-12-05","current":-14.825843,"twenty":-17.466248,"median":-13.119398,"eighty":-8.337771,"marketCap":872990135},{"date":"2025-12-12","current":-13.01911,"twenty":-17.42774,"median":-13.221067,"eighty":-8.354198,"marketCap":766604240},{"date":"2025-12-19","current":-9.070865,"twenty":-17.407695,"median":-13.037789,"eighty":-8.414622,"marketCap":534119770},{"date":"2025-12-26","current":-9.108063,"twenty":-17.390007,"median":-12.866196,"eighty":-8.500376,"marketCap":536310068},{"date":"2026-01-02","current":-8.502276,"twenty":-17.333409,"median":-12.777948,"eighty":-8.502276,"marketCap":500639504},{"date":"2026-01-09","current":-8.098418,"twenty":-17.315721,"median":-12.328345,"eighty":-8.502276,"marketCap":476859127},{"date":"2026-01-16","current":-9.639455,"twenty":-17.280347,"median":-12.249123,"eighty":-8.498134,"marketCap":567600037},{"date":"2026-01-23","current":-11.302713,"twenty":-17.228465,"median":-12.093174,"eighty":-8.501448,"marketCap":665537640},{"date":"2026-01-30","current":-9.448154,"twenty":-17.210778,"median":-11.871572,"eighty":-8.502276,"marketCap":556335648},{"date":"2026-02-06","current":-7.42355,"twenty":-17.195449,"median":-11.633633,"eighty":-8.39709,"marketCap":437120866},{"date":"2026-02-13","current":-6.892157,"twenty":-17.156729,"median":-11.509772,"eighty":-8.290687,"marketCap":405830897},{"date":"2026-02-20","current":-6.403276,"twenty":-17.117721,"median":-11.432889,"eighty":-8.236123,"marketCap":377044126},{"date":"2026-02-27","current":-7.184423,"twenty":-17.08343,"median":-11.396709,"eighty":-8.118629,"marketCap":423040380},{"date":"2026-03-06","current":-6.40859,"twenty":-17.073997,"median":-11.306259,"eighty":-7.995871,"marketCap":377357026},{"date":"2026-03-13","current":-6.281056,"twenty":-17.036729,"median":-11.290275,"eighty":-7.848663,"marketCap":369847433},{"date":"2026-03-20","current":-6.105697,"twenty":-16.999628,"median":-11.252126,"eighty":-7.671592,"marketCap":359521743},{"date":"2026-03-27","current":-3.413108,"twenty":-16.980184,"median":-11.233899,"eighty":-7.489126,"marketCap":280308282}],"updateTime":1774706646997},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LENZ\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2621640330","title":"Intensity Therapeutics issued new patent in the US","url":"https://stock-news.laohu8.com/highlight/detail?id=2621640330","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621640330?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:12","pubTimestamp":1774354363,"startTime":"0","endTime":"0","summary":"Intensity Therapeutics (INTS) provided an update on its patent portfolio including the recent issuance in December 2025 of a new patent in the U.S....","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/intensity-therapeutics-issued-new-patent-in-the-us-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/intensity-therapeutics-issued-new-patent-in-the-us-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","BK4539","INTS","LENZ"],"gpt_icon":0},{"id":"2621123064","title":"LENZ Therapeutics Q4 net loss widens on VIZZ launch costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2621123064","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621123064?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:11","pubTimestamp":1774354310,"startTime":"0","endTime":"0","summary":"LENZ Therapeutics Q4 net loss widens on VIZZ launch costsOverviewUS pharmaceutical company's Q4 2025 product revenue reached $1.6 mln after VIZZ launchNet loss for Q4 2025 widened to $35.9 mln, reflec","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nL1N40C0IQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LENZ","BK4007","BK4539"],"gpt_icon":0},{"id":"2621064669","title":"LENZ Q4 net loss rises 184% to USD 35.9 million, SG&A expenses jump 323% to USD 40 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2621064669","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621064669?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:04","pubTimestamp":1774353874,"startTime":"0","endTime":"0","summary":"Lenz published a press release reporting fourth-quarter and full-year 2025 financial results and recent corporate highlights.Q4 product sales, net were USD 1.6 million, while net loss was USD 35.9 million, or USD 1.16 per share.Full-year total revenue was USD 19.09 million, including USD 17.5 million of license revenue and USD 1.6 million of product sales, net.FY SG&A expenses rose to USD 91.1 million and FY R&D expenses fell to USD 18.7 million, reflecting commercial launch buildout and the conclusion of the Phase 3 CLARITY study and subsequent FDA approval of VIZZ.Cash, cash equivalents and marketable securities totaled USD 292.3 million, and management said this is expected to fund operations to post-launch positive operating cash flow.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be int","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL6NHY58:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","LENZ","BK4007"],"gpt_icon":0},{"id":"2621806433","title":"LENZ Therapeutics Q4 EPS $(1.16) Misses $(0.96) Estimate, Sales $1.588M Miss $1.886M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2621806433","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621806433?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:01","pubTimestamp":1774353685,"startTime":"0","endTime":"0","summary":"LENZ Therapeutics (NASDAQ:LENZ) reported quarterly losses of $(1.16) per share which missed the analyst consensus estimate of $(0.96) by 20.83 percent. This is a 152.17 percent decrease over losses of $(0.46) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51427800/lenz-therapeutics-q4-eps-1-16-misses-0-96-estimate-sales-1-588m-miss-1-886m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"gpt_icon":0},{"id":"2621657064","title":"Lenz Therapeutics Inc - Q4 2025 Product Revenue Approx $1.6 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2621657064","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621657064?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:00","pubTimestamp":1774353606,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nTUA4J7JW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","BK4007","LENZ"],"gpt_icon":0},{"id":"2621838064","title":"Lenz Therapeutics Q4 Net Income USD -35.896 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2621838064","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621838064?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:00","pubTimestamp":1774353602,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nPLXA8DFE8:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LENZ","BK4007","BK4539","BK4139"],"gpt_icon":0},{"id":"2621064895","title":"Lenz Therapeutics Q4 Income From Operations USD -38.463 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2621064895","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621064895?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:00","pubTimestamp":1774353602,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nPLXA8DFE8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4007","LENZ","BK4139"],"gpt_icon":0},{"id":"2621061716","title":"Lenz Therapeutics Q4 Operating Expenses USD 40.051 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2621061716","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621061716?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:00","pubTimestamp":1774353602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nPLXA8DFE8:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","LENZ","BK4007"],"gpt_icon":0},{"id":"2621384064","title":"Press Release: Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2621384064","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621384064?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:00","pubTimestamp":1774353600,"startTime":"0","endTime":"0","summary":"RADNOR, Pa., March 24, 2026  -- Mineralys Therapeutics, Inc. , a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease , obstructive sleep apnea  and other diseases driven by dysregulated aldosterone, announced the appointment of Jeffrey A. Munsie as Chief Legal Officer.\"Jeff brings deep life sciences experience across critical stages of growth, from preclinical through commercialization,\" said Jon Congleton, Chief Executive Officer of Mineralys. \"His strategic counsel, strong leadership, and proven track record will be instrumental in strengthening our legal and compliance capabilities.\". Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, hi","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLYS","BK4539","LENZ","BK4007","BK4139"],"gpt_icon":0},{"id":"2621061010","title":"Press Release: LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2621061010","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621061010?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:00","pubTimestamp":1774353600,"startTime":"0","endTime":"0","summary":"Launched VIZZ  1.44% for the treatment of presbyopia in October 2025 and generated net product revenues of $1.6 million in the first quarter of launch. On pace for over 45,000 paid prescriptions filled from launch through Q1 2026, written by more than 10,000 prescribing eye care professionals. Compelling real-world performance of VIZZ, combined with broad prescriber uptake and encouraging early refill trends, reinforces confidence in its best-in-class profile and establishment of a durable new category. \"We are encouraged by the early performance of VIZZ. We undoubtedly have a product that works, with broad prescriber uptake and early signs of encouraging refill dynamics reinforcing its best-in-class profile,\" said Eef Schimmelpennink, President and Chief Executive Officer of LENZ Therapeutics. \"We are clearly establishing a new category, with physicians building new habits of identifying appropriate patients and incorporating VIZZ into routine discussions. To accelerate this, we are l","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","LENZ","MAA","BK4232","BK4215","BK4539","BK4588","BK4585","BK4081","BK4007","EMA","BK4139","BK4022"],"gpt_icon":0},{"id":"2621681061","title":"CAMP4 Therapeutics Adds Veteran CFO MacLean to Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2621681061","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621681061?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:29","pubTimestamp":1774351783,"startTime":"0","endTime":"0","summary":"The latest update is out from CAMP4 Therapeutics Corporation ( ($CAMP) ). On March 18, 2026, CAMP4 Therapeutics’ board appointed veteran biotech fi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/camp4-therapeutics-adds-veteran-cfo-maclean-to-board?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/camp4-therapeutics-adds-veteran-cfo-maclean-to-board?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4139","BK4539","BK4020","CAMP","LENZ"],"gpt_icon":0},{"id":"2621696620","title":"Wedbush Raises Price Target on Avalo Therapeutics to $29 From $28, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2621696620","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621696620?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:18","pubTimestamp":1774351098,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics (AVTX) has an average rating of buy and mean price target of $36.38, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ"],"gpt_icon":0},{"id":"2621087065","title":"Context Therapeutics price target raised to $7 from $4 at Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2621087065","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621087065?lang=en_us&edition=fundamental","pubTime":"2026-03-24 18:35","pubTimestamp":1774348512,"startTime":"0","endTime":"0","summary":"Piper Sandler raised the firm’s price target on Context Therapeutics (CNTX) to $7 from $4 and keeps an Overweight rating on the shares after the co...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/context-therapeutics-price-target-raised-to-7-from-4-at-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/context-therapeutics-price-target-raised-to-7-from-4-at-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"gpt_icon":0},{"id":"2621063440","title":"Avalo Therapeutics Price Target Maintained With a $40.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2621063440","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621063440?lang=en_us&edition=fundamental","pubTime":"2026-03-24 18:06","pubTimestamp":1774346760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AVTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 24, 2026 06:06 ET (10:06 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"gpt_icon":0},{"id":"2621660920","title":"Serina Therapeutics to Present at the 38th Annual Roth Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2621660920","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621660920?lang=en_us&edition=fundamental","pubTime":"2026-03-24 18:00","pubTimestamp":1774346400,"startTime":"0","endTime":"0","summary":"HUNTSVILLE, AL, March  24, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platformdrug optimi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/24/3261012/0/en/Serina-Therapeutics-to-Present-at-the-38th-Annual-Roth-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4539","BK4139","LENZ"],"gpt_icon":0},{"id":"2621050056","title":"Relmada Therapeutics initiated with an Overweight at Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2621050056","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621050056?lang=en_us&edition=fundamental","pubTime":"2026-03-24 17:00","pubTimestamp":1774342812,"startTime":"0","endTime":"0","summary":"Piper Sandler initiated coverage of Relmada Therapeutics (RLMD) with an Overweight rating and $12 price target The firm says the company is advanci...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/relmada-therapeutics-initiated-with-an-overweight-at-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/relmada-therapeutics-initiated-with-an-overweight-at-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"gpt_icon":0},{"id":"2621057464","title":"Cutia Therapeutics' Loss Narrows in 2025 as Revenue Rises","url":"https://stock-news.laohu8.com/highlight/detail?id=2621057464","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621057464?lang=en_us&edition=fundamental","pubTime":"2026-03-24 16:52","pubTimestamp":1774342325,"startTime":"0","endTime":"0","summary":"Cutia Therapeutics  posted a loss attributable to owners of 340.2 million yuan for 2025, narrowing from a loss of 433.8 million yuan a year earlier, according to a Tuesday Hong Kong bourse filing.Loss per share at the pharmaceutical company came in at 1.03 yuan, compared with 1.41 yuan a year earlier.Revenue rose to 336.2 million yuan from 279.6 million yuan in 2024.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ"],"gpt_icon":0},{"id":"2621105732","title":"Cutia Therapeutics Boosts Revenue and Margins as Key Dermatology Products Launch in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2621105732","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621105732?lang=en_us&edition=fundamental","pubTime":"2026-03-24 16:39","pubTimestamp":1774341541,"startTime":"0","endTime":"0","summary":"Cutia Therapeutics ( ($HK:2487) ) has shared an update. Cutia Therapeutics reported that two key dermatology products, CU-40102 topical finasteride...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cutia-therapeutics-boosts-revenue-and-margins-as-key-dermatology-products-launch-in-2025?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cutia-therapeutics-boosts-revenue-and-margins-as-key-dermatology-products-launch-in-2025?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"gpt_icon":0},{"id":"2621053696","title":"Qyuns Therapeutics Invests 100 Million Yuan in Wealth Management Product","url":"https://stock-news.laohu8.com/highlight/detail?id=2621053696","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621053696?lang=en_us&edition=fundamental","pubTime":"2026-03-24 13:40","pubTimestamp":1774330813,"startTime":"0","endTime":"0","summary":"Qyuns Therapeutics  said it invested 100 million yuan in a wealth management product offered by Shanghai Pudong Development Bank, according to a Hong Kong bourse filing Monday.Shares of the biopharmaceutical company gained over 3% in afternoon trade Tuesday.The product matures Sept. 23 and offers a guaranteed yield of 0.95% and a floating yield of 0% or 1.05% in the mid range or 1.25% in the high range.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","BK4007","BK1161","BK4139","02509","LENZ"],"gpt_icon":0},{"id":"2621203332","title":"Avalo Therapeutics: Attractive Risk‑Reward in Hidradenitis Suppurativa Driven by Abdakibart’s Differentiated IL‑1β Profile and Upcoming Phase 2 LOTUS Readout","url":"https://stock-news.laohu8.com/highlight/detail?id=2621203332","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621203332?lang=en_us&edition=fundamental","pubTime":"2026-03-24 07:36","pubTimestamp":1774308961,"startTime":"0","endTime":"0","summary":"Analyst Julian Harrison from BTIG maintained a Buy rating on Avalo Therapeutics and keeping the price target at $40.00. Julian Harrison has given h...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/avalo-therapeutics-attractive-risk‑reward-in-hidradenitis-suppurativa-driven-by-abdakibarts-differentiated-il‑1β-profile-and-upcoming-phase-2-lotus-readout-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/avalo-therapeutics-attractive-risk‑reward-in-hidradenitis-suppurativa-driven-by-abdakibarts-differentiated-il‑1β-profile-and-upcoming-phase-2-lotus-readout-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","LENZ","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":13,"pageCount":5,"totalSize":260,"code":"91000000","status":"200"}]}}